Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies
- 1 November 2020
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 318, 67-73
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Europe
- British Heart Foundation
- European Union
- Leducq Foundation
- German Centre for Heart Research
- Sanofi-Aventis
- Boehringer Ingelheim
- Bayer
- BMS/Pfizer
- Daiichi Sankyo
- Novartis
- MSD
- Portola
This publication has 32 references indexed in Scilit:
- Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty RegistryEuropean Heart Journal, 2012
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial FibrillationJAMA, 2011
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 yearsEuropean Heart Journal, 2008
- Atrial fibrillation and obesity—results of a meta-analysisAmerican Heart Journal, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- The Obesity ParadoxArchives of internal medicine (1960), 2005
- Obesity and the Risk of New-Onset Atrial FibrillationJAMA, 2004
- Association between obesity and a prothrombotic state: the Framingham Offspring StudyThrombosis and Haemostasis, 2004